SCHEDULE: Adage Capital Amends TScan Therapeutics Stake
Beneficial Ownership Report
Adage Capital Management, L.P. and its principals reported a 2.52% beneficial ownership stake in TScan Therapeutics, Inc., primarily through warrants.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 1,350,000 shares of TScan Therapeutics, Inc. Voting Common Stock.
- This ownership represents 2.52% of the company's outstanding Voting Common Stock.
- The reported shares are issuable upon the exercise of warrants held by Adage Capital Partners, L.P.
- The percentage of class is calculated based on 52,314,039 shares of Voting Common Stock outstanding as of April 30, 2025, as reported in TScan Therapeutics' Form 10-Q filed on May 6, 2025, assuming the exercise of the reported warrants.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing (Schedule 13G Amendment) disclosing beneficial ownership. It contains factual information about an existing stake and does not convey positive or negative sentiment regarding the company's performance or future prospects.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by an institutional investor in a biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape, but rather reflects an investment position within the sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can be a factor in market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 04/30/2025 | Date as of which TScan Therapeutics, Inc. reported 52,314,039 shares of Voting Common Stock outstanding in its Form 10-Q. |
| 05/06/2025 | Date TScan Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the period ended March 31, 2025. |
| 06/30/2025 | Date of event which required the filing of this statement (Amendment No. 3). |
| 08/12/2025 | Date of filing of this Schedule 13G Amendment No. 3. |
Keywords
TScan Therapeutics, Adage Capital Management, Beneficial Ownership, Schedule 13G, Warrants, Common Stock, Institutional Ownership, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.